Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1126]

Plasma miR371 detects MRD and early relapse of germ cell tumours

Dr Lucia Nappi - University of British Columbia, Vancouver, Canada

Plasma miR371 detects MRD and early relapse of germ cell tumours ( Dr Lucia Nappi - University of British Columbia, Vancouver, Canada )

Comparative cost-effectiveness of alternative imaging and surveillance...

Prof Robert Huddart - Royal Marsden NHS Foundation Trust, London, UK

Comparative cost-effectiveness of alternative imaging and surveillance schedules for testicular seminoma ( Prof Robert Huddart - Royal Marsden NHS Foundation Trust, London, UK )

Adaptive image-guided radiotherapy in muscle-invasive bladder cancer shows low...

Prof Robert A Huddart - Royal Marsden NHS Foundation Trust, London, UK

Adaptive image-guided radiotherapy in muscle-invasive bladder cancer shows low toxicity and good outcomes ( Prof Robert A Huddart - Royal Marsden NHS Foundation Trust, London, UK )

ASCO GU 2023: Latest updates in mRCC

Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor...

ASCO GU 2023: Latest updates in mRCC ( Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor Grünwald and Prof Toni Choueiri )

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in...

Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC ( Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France )

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Nivolumab and salvage nivolumab plus ipilimumab for aRCC

Prof Michael Atkins - Georgetown Lombardi Comprehensive Cancer Center...

Nivolumab and salvage nivolumab plus ipilimumab for aRCC ( Prof Michael Atkins - Georgetown Lombardi Comprehensive Cancer Center, Georgetown, USA )

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Anti-PSMA antibody radiolabeled with 177Lu improves MFS in high-risk nmCRPC

Prof Scott Tagawa - Weill Cornell Medicine, New York City, USA

Anti-PSMA antibody radiolabeled with 177Lu improves MFS in high-risk nmCRPC ( Prof Scott Tagawa - Weill Cornell Medicine, New York City, USA )

ASCO GU 2023: Latest real world data in prostate cancer

Prof Phil Cornford and Prof Laura-Maria Krabbe

ASCO GU 2023: Latest real world data in prostate cancer ( Prof Phil Cornford and Prof Laura-Maria Krabbe )

Erdafitinib demonstrates efficacy in intermediate-risk non–muscle-invasive...

Prof Siamak Daneshmand - University of Southern California, Los Angeles, USA

Erdafitinib demonstrates efficacy in intermediate-risk non–muscle-invasive bladder cancer with FGFR alterations ( Prof Siamak Daneshmand - University of Southern California, Los Angeles, USA )

More from ecancer